22nd Century Group's Q1 Revenue Plummets 31%, Flagship VLN® Sales Hit Zero Amid Widening Losses
XXII is trading near its 52-week low of $0.79 (6.6% above the low).
Summary
22nd Century Group reported a sharp 31.1% year-over-year revenue decline to $4.1 million in Q1 2026, alongside widening operating losses and a critical $0.0 million in net revenue from its flagship VLN® cigarettes, intensifying concerns about its financial viability.
Key Events · Earnings and Guidance · XXII
-
Significant Revenue Decline
Net revenues fell 31.1% year-over-year to $4.1 million for the first quarter ended March 31, 2026.
-
Worsening Profitability
Operating loss increased to $3.0 million and Adjusted EBITDA loss widened to $2.6 million compared to the prior year quarter.
-
Zero VLN® Cigarette Revenue
The company's flagship VLN® product recorded $0.0 million in net revenues for the quarter, following initial stocking orders in Q4 2025, offset by customer returns and product exchanges.
-
Cash Position Amid Dilution
Ended the quarter with $9.5 million in cash and equivalents, against a backdrop of recently authorized highly dilutive At-The-Market offerings.
Analysis · XXII · Manufacturing
This 8-K filing reveals a deeply concerning financial performance for 22nd Century Group, with net revenues plummeting over 31% year-over-year and operating losses widening. Most critically, the company reported zero net revenue from its flagship VLN® cigarettes, a product central to its harm reduction strategy and future growth. These results significantly exacerbate the 'going concern' doubts previously disclosed in the company's 10-K and underscore the urgent need for the highly dilutive At-The-Market offerings recently authorized. Investors should view these results as a strong negative signal regarding the company's operational execution and financial stability, suggesting continued pressure on the stock.
How filings like this one have moved
In the 30 days to Oct 5, 2026, 42.7% of the 288 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.53%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, XXII was trading at $0.84 on NASDAQ in the Manufacturing sector, with a market capitalization of approximately $613.7K. The 52-week trading range was $0.79 to $483.00. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.